Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

MOBILE, Ala. (WALA) -There is now a new treatment option for the estimated 2 million people in the United States living with moderate-to-severe plaque psoriasis whose symptoms may make day-to-day life ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Decreased coronary flow was associated with severe psoriasis, according to one study. The largest study to date on the relationship between severe psoriasis and coronary microvascular dysfunction (CMD ...